(+/-)-methyl 2-(2,3-dihydrospiro[indene-1,4'-piperidine]-3-yl)acetate | 1009374-71-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (+/-)-methyl 2-(2,3-dihydrospiro[indene-1,4'-piperidine]-3-yl)acetate
• 英文别名: Methyl 2-(2,3-dihydrospiro[indene-1,4'-piperidin]-3-yl)acetate；methyl 2-spiro[1,2-dihydroindene-3,4'-piperidine]-1-ylacetate
• CAS: 1009374-71-3
• 化学式: C₁₆H₂₁NO₂
• 分子量: 259.348
• InChiKey: FNRMGNFBNKTIQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+/-)-methyl 2-(2,3-dihydrospiro[indene-1,4'-piperidine]-3-yl)acetate 、 2-adamantyl isocyanate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (+/-)-methyl 2-(1'-((2-adamantyl)carbamoyl)-2,3-dihydrospiro[indene-1,4'-piperidine]-3-yl)acetate
  参考文献：
  名称：

  Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design

  摘要：

  Structure-guided drug design led to the identification of a class of spirocyclic ureas which potently inhibit human 11 beta-HSD1 in vitro. Lead compound 10j was shown to be orally bioavailable in three species, distributed into adipose tissue in the mouse, and its (R) isomer 10j2 was efficacious in a primate pharmacodynamic model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.082
• 作为产物：
  描述：

  甲醇 、 1’-(叔丁氧羰基)-2,3-二氢螺[1H-茚-1,4’-哌啶]-3-乙酸 在 氯化亚砜 作用下， 以94%的产率得到(+/-)-methyl 2-(2,3-dihydrospiro[indene-1,4'-piperidine]-3-yl)acetate
  参考文献：
  名称：

  INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

  摘要：

  这项发明涉及到式(I*)的新化合物，其药用盐以及药物组合物，这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。

  公开号：

  US20110034455A1

文献信息

• ANTAGONISTS OF PGD2 RECEPTORS
  申请人：Stearns Brian Andrew

  公开号：US20100298368A1

  公开（公告）日：2010-11-25

  Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD 2 activated chemoattractant receptor-homologous molecule expressed on TH 2 cells (CRTH2). Also described herein are methods of using such CRTH2 modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 mediated conditions or diseases.

  本文描述了一些化合物和含有这些化合物的药物组合物，这些化合物能够调节PGD2激活的TH2细胞表达的趋化因子受体同源分子（CRTH2）。本文还描述了使用这种CRTH2调节剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖于PGD2或由PGD2介导的疾病或病情。
• US8927715B2
  申请人：——

  公开号：US8927715B2

  公开（公告）日：2015-01-06
• [EN] INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] INHIBITEURS DE LA 11ß-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2008024497A2

  公开（公告）日：2008-02-28

  [EN] This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11ß- HSDl in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
  [FR] Cette invention concerne de nouveaux composés de formule (I*), des sels acceptables du point de vue pharmaceutique de ceux-ci et des compositions pharmaceutiques de ceux-ci, lesquels sont utiles pour le traitement thérapeutique de maladies associées à la modulation ou à l'inhibition de la 11ß-HSD1 chez des mammifères. L'invention concerne en outre des compositions pharmaceutiques des nouveaux composés et des procédés d'utilisation de ceux-ci dans la réduction ou la régulation de la production de cortisol dans une cellule ou l'inhibition de la conversion de cortisone en cortisol dans une cellule.
• [EN] ANTAGONISTS OF PGD2 RECEPTORS<br/>[FR] ANTAGONISTES DE RÉCEPTEURS PGD2
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2009061681A2

  公开（公告）日：2009-05-14

  Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases.
• INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Claremon David A.

  公开号：US20110034455A1

  公开（公告）日：2011-02-10

  This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  这项发明涉及到式(I*)的新化合物，其药用盐以及药物组合物，这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。